MGA vs MRNA Comparison

Magna International prides itself on an entrepreneurial culture and a corporate constitution that outlines the distribution of profits to various stakeholders. This automotive supplier's product groups include exteriors, interiors, seating, roof systems, body and chassis, powertrain, vision and electronic systems, closure systems, electric vehicle systems, tooling and engineering, and contract vehicle assembly. In 2024, 48% of Magna's USD 42.8 billion of revenue came from North America, while Europe accounted for approximately 37% and Asia the remainder. The firm's top six customers constituted 72.9% of revenue, with the top three being GM, Mercedes, and Ford. GM was the largest contributor at 15.4%. Magna was founded in 1957, has over 170,000 employees, and is based in Aurora, Ontario.

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.